A large-scale real-world study shows Amgen's Repatha outperforms ezetimibe by reducing heart attack risk by 20%, offering new clinical data to guide cardiovascular treatment strategies.
Repatha reduced heart attack risk by 20% versus ezetimibe in a real-world study of over half a million adults with heart disease. This strengthens the clinical case for Repatha, potentially supporting higher sales for Amgen. However, the study is real-world evidence, not a new pivotal trial, and financial impact depends on payer and prescribing uptake.
The study compared Repatha with ezetimibe in more than half a million adults with heart disease.
Repatha lowered the risk of heart attacks by 20% compared with ezetimibe.
Amgen's Repatha demonstrated a 20% reduction in heart attack risk compared to ezetimibe in a real-world study involving over 500,000 adults with heart disease. These findings provide significant clinical evidence to support non-statin treatment decisions for patients managing cardiovascular conditions.
The study compared the real-world outcomes of Repatha with ezetimibe in more than half a million adults living with heart disease.
The study found that Repatha lowered the risk of heart attacks by 20% compared with ezetimibe.